These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19894352)

  • 1. [Molecular-targeted drugs. 1) Indications and the application of molecular-targeted drugs in hematological diseases].
    Okawa Y; Aiba K
    Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1908-17. PubMed ID: 19894352
    [No Abstract]   [Full Text] [Related]  

  • 2. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
    Meng FY; Fu YB
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
    [No Abstract]   [Full Text] [Related]  

  • 3. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.
    Piccaluga PP; Arpinati M; Candoni A; Laterza C; Paolini S; Gazzola A; Sabattini E; Visani G; Pileri SA
    Leuk Lymphoma; 2011 Feb; 52(2):325-7. PubMed ID: 21077738
    [No Abstract]   [Full Text] [Related]  

  • 4. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
    Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
    Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal antibody therapies for acute leukemia].
    Takeshita A; Ono R
    Rinsho Ketsueki; 2002 May; 43(5):353-6. PubMed ID: 12096485
    [No Abstract]   [Full Text] [Related]  

  • 6. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
    Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
    Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
    Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O
    Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antibody therapy for acute leukemia].
    Takeshita A
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():408-15. PubMed ID: 17474439
    [No Abstract]   [Full Text] [Related]  

  • 9. Monoclonal antibodies in the treatment of myelogenous leukemias.
    Scheinberg DA
    Cancer Treat Res; 1993; 64():213-32. PubMed ID: 7680876
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibody-targeted chemotherapy of relapsed AML.
    Mineur P; Lejeune C; Hennaux V; Eten C
    Br J Haematol; 2003 Apr; 121(1):195-6. PubMed ID: 12670356
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic monoclonal antibodies in onco-hematology].
    Cartron G; Rossi JF
    Med Sci (Paris); 2009 Dec; 25(12):1085-9. PubMed ID: 20035683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia.
    Miller JL
    Am J Health Syst Pharm; 2000 Jul; 57(13):1202, 1204. PubMed ID: 10902059
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
    Caron PC; Scheinberg DA
    Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
    Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
    Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies.
    Matthews DC; Appelbaum FR; Press OW; Eary JF; Bernstein ID
    Cancer Treat Res; 1997; 77():121-39. PubMed ID: 9071501
    [No Abstract]   [Full Text] [Related]  

  • 17. New developments in the treatment of acute myeloid leukemia.
    Radich J; Sievers E
    Oncology (Williston Park); 2000 Nov; 14(11A):125-31. PubMed ID: 11195406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.
    Frankel AE; Sievers EL; Scheinberg DA
    Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
    Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
    Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
    [No Abstract]   [Full Text] [Related]  

  • 20. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
    Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
    Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.